A new study led by scientists at Beth Israel Deaconess Medical Center (BIDMC) shows that an HIV -
1 vaccine regimen, involving a viral vector boosted with a purified envelope protein, provided complete protection in half of the vaccinated non-human primates (NHPs) against a series of six repeated challenges with simian immunodeficiency virus (SIV), a virus similar to HIV that infects NHPs.
Not exact matches
An HIV -
1 version of the promising
vaccine regimen is now being evaluated in an ongoing Phase
1 / 2a international clinical study.
Based on these pre-clinical data, the HIV -
1 version of this
vaccine regimen is now being evaluated in an ongoing Phase
1 / 2a international clinical study sponsored by Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
• RV2
17 (ECHO): HIV -
1 Prevalence, Incidence, Cohort Retention, and Host Genetics and Viral Diversity in High Risk Cohorts in East Africa • Infectious Disease Surveillance (HIV, TB and Malaria) and Cohort Development Among Urban and Rural Communities • Karolinska Institute
vaccine study in Tanzania testing a prime - boost HIV
vaccine regimen using unadjuvanted DNA
vaccines followed by a Modified Vaccinia Ankara (MVA), which was developed by MHRP and NIAID.